ALL GOOD THINGS COME TO AN END! 

After a decade of exciting research Tanezumab is dead. So are most of its siblings. Fasinumab is the lone survivor in this family of Nerve Growth Factor inhibitors. These drugs held a lot of promise and hope for people with advanced degenerative arthritis and chronic pain. But they were killed by the FDA reviewers because a few more people needed joint replacement surgery sooner than expected. 

There are many far dangerous and less beneficial drugs in the market, killing people by the thousands...

https://rheumnow.com/news/pfizerlilly-pull-tanezumab-development?utm_source=RheumNow+Newsletter&utm_campaign=8f8209a912-EMAIL_CAMPAIGN_2021_10_26_09_04&utm_medium=email&utm_term=0_11adbca03a-8f8209a912-243777661